GEN Exclusives

More »

GEN News Highlights

More »
Jun 27, 2007

Ipsen Grants Technology to and Takes Stake in PregLem

  • PregLem signed a licensing agreement with Ipsen under which Ipsen will grant PregLem worldwide development and commercialization rights to certain Ipsen compounds, for use in reproductive medicine only.

    Sutrepa (an affiliate of Ipsen) has taken a minority equity stake in PregLem and will appoint a representative to its board of directors. PregLem is a biopharmaceutical company specialized in reproductive medicine. It is focused on the development and commercialization of innovative compounds for the treatment of benign gynecological conditions and infertility.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »